Back to resultsNordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Primary Purpose
Breast Cancer, Triple Negative Breast Neoplasms
Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab
epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab
Sponsored by
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring Breast neoplasms, Triple negative breast neoplasms, Neoadjuvant treatment, Translational research, Pathologic response, Pathologic complete response, epirubicin, cyclophosphamide, paclitaxel, carboplatin, capecitabine, Survival outcomes, Homologous repair deficiency, pembrolizumab
Eligibility Criteria
Inclusion Criteria:
- Signed written informed consent approved by the Ethical Review Board (IRB).
- Age 18 to 75 years.
- Histologically confirmed unilateral adenocarcinoma of the breast where neoadjuvant chemotherapy followed by definitive surgery is planned.
- Node positive disease (N1-3) or if clinically N0 Tumor size >20 mm.
ER negative tumor defined by at least one the following:
- ER < 1% cells positive by immuno-histochemistry (IHC)
- ER < 10% cells positive by IHC and progesterone receptor) progesterone receptor (PgR) < 10% cells positive by IHC
Human Epidermal Growth Factor Receptor2 (HER2)-normal tumor defined by at least one of the following:
- HER2 0 or 1+ by immunohistochemistry
- HER2 2+ by IHC and HER2 to centromere 17 ratio < 2.0 and/or less than 6 copies by in situ hybridization [ISH]).
Comment: Patients with 3+ IHC for HER2 will not be included irrespective of the outcome of in situ hybridization (ISH)-analysis.
- Consent for germline mutation screening for BRCA1, BRCA2 and other inherited breast cancer associated genes.
- World Health Organization (WHO) performance status 0 or 1.
- Negative pregnancy test in women of childbearing potential (premenopausal or <12 months of amenorrhea post-menopause and who have not undergone surgical sterilization).
- Willingness by the patient to undergo treatment according to the protocol and study related procedures.
Exclusion Criteria:
- Clinical or radiological signs of metastatic disease.
- Clinically inflammatory breast cancer
- History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or non-melanoma skin cancer.
- Previous chemotherapy for cancer or other malignant disease.
- Charlson comorbidity index, excluding score for malignancy: (CCI) > 2, Comment: In patients 70-75 a CCI = 3 is allowed, see appendix B.
Inadequate organ function, suggested by the following laboratory results:
a. Absolute neutrophil count < 1,5 x 109/l b Platelet count < 100 x 109/l c Haemoglobin < 90 g/L d Total bilirubin greater than the upper limit of normal (ULN) unless the patient has documented Gilbert´s syndrome e Aspartate Aminotransferase (AST), (SGOT) and/or Alanine Aminotransferase (ALT), (SGPT) > 2,5 x ULN f AST (SGOT) and/or ALT (SGPT) > 1,5 x ULN with concurrent serum alkaline phosphatase (ALP) > 2,5 x ULN g Serum creatinine clearance < 50 mL/min
- Concurrent peripheral neuropathy of grade 3 or greater (NCI-CTCAE, Version 5.0)
- Patient who is actively breast feeding.
- Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
Sites / Locations
- Odense University HospitalRecruiting
- Vejle Hospital
- Aalborg UniversitetshospitaRecruiting
- RigshospitaletRecruiting
- Sydvestjysk SygehusRecruiting
- Nordsjællands HospitalRecruiting
- Regionsjælland Næstved SygehusRecruiting
- Sønderborg sygehusRecruiting
- Vejle syghusRecruiting
- Centralsjukhuset i Kristianstad
- Södra Älvsborgs HospitalRecruiting
- Gävle hospital, Department of OncologyRecruiting
- Sahlgrenska University Hospital, Department of OncologyRecruiting
- Halmstad Hospital, Department of Surgery
- Ryhov HospitalRecruiting
- Karlstad HospitalRecruiting
- Skåne University Hospital, Department of OncologyRecruiting
- Capio S:t Göran Hospital, Department of OncologyRecruiting
- Södersjukhuset, Department of OncologyRecruiting
- Sundsvall hospitalRecruiting
- Norrland University Hospital, Department of OncologyRecruiting
- Academical Hospital, Department of OncologyRecruiting
- Västmanlands Hopsital VästeråsRecruiting
- Växjö Hospital, Department of OncologyRecruiting
- Örebro University Hospital, Department of OncologyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Arm A (Platinum-based dose dense EC):
Arm B (Platinum-based with capecitabine):
Arm Description
ddEC x 4 + pembrolizumab→ PK x 4 + pembrolizumab, Two-weekly epirubicin/cyclophosphamide (EC) x 4 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2), followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2). Pembrolizumab is given as a 400 mg iv dosis every 6 weeks for the duration of preoperative chemotherapy.*
CEX x 4→ PK x 4, Three-weekly cyclophosphamide/epirubicin/capecitabine (CEX) (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 and capecitabine 900 mg/m2) x 4, followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).Pembrolizumab is given as a 400 mg iv dosis every 6 weeks for the duration of preoperative chemotherapy.* *The addition of pembrolizumab is strongly recommended to all participating patients. However, patients with a documented contraindication, or unwilling to receive immunotherapy may be included in the study without the administration of pembrolizumab.
Outcomes
Primary Outcome Measures
Pathological complete response rate.
Rate of pathological complete response, allowing residual dcis, at surgery after preoperative chemotherapy.
Primary translational outcome.
Pathological complete response rate, allowing residual dcis, stratified for homologous repair deficiency.
Secondary Outcome Measures
Invasive Disease Free Survival (IDFS)
Invasive disease-free survival
Overall Survival (OS)
Overall survival
Breast Cancer Specific Survival (BCSS)
Breast cancer specific survival
Distant Recurrence Free Survival (DRFS)
Distant recurrence free survival.
Dose intensity
Actual dosis/dosis per protocol
Toxicity according to CTCAE version 5.0
Rate of included patients with toxicity grade 3 or greater during study treatment
Full Information
NCT ID
NCT04335669
First Posted
December 2, 2019
Last Updated
March 23, 2023
Sponsor
Lund University Hospital
Collaborators
Swedish Breast Cancer Group, Danish Breast Cancer Cooperative Group, Finnish Breast Cancer Group, Icelandic Breast Cancer Group
1. Study Identification
Unique Protocol Identification Number
NCT04335669
Brief Title
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Official Title
A Translational Randomized Phase III Study Exploring the Effect of the Addition of Capecitabine to Carboplatine Based Chemotherapy in Early "Triple Negative" Breast Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 20, 2019 (Actual)
Primary Completion Date
June 25, 2023 (Anticipated)
Study Completion Date
June 30, 2035 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lund University Hospital
Collaborators
Swedish Breast Cancer Group, Danish Breast Cancer Cooperative Group, Finnish Breast Cancer Group, Icelandic Breast Cancer Group
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Primary aim: To compare the effect on pathologic complete response (pCR) rate of adding capecitabine to carboplatin based preoperative chemotherapy in early ER-negative and HER2-negative breast cancer. Pembrolizumab is allowed in both arms after approval for TNBC 2022.
Detailed Description
Primary aim: Pathological complete response rate after preoperative chemotherapy is the primary end-point of the study, which will be evaluated by comparing the effects of neoadjuvant administration of a carboplatin-based treatment and treatment adding capecitabine on pCR. After the approval of pembrolizumab in the preoperative treatment of early TNBC in 2022 the study will consist of two cohorts, one (cohort 1) without the addition of pembrolizumab, and one (cohort 2) with the addition of pembrolizumab to both study arms. The primary evaluation will be performed on the entire study population including both cohorts.
Primary translational aim: To investigate if the effects of the treatments depend on homologous repair deficiency (HRD)-status. More specifically, the aim is to test for differential effect of the two treatments on pCR for HRD-negative (HRD low and intermediate by oncoscan) and HRD-positive (HRD high by oncoscan) patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Triple Negative Breast Neoplasms
Keywords
Breast neoplasms, Triple negative breast neoplasms, Neoadjuvant treatment, Translational research, Pathologic response, Pathologic complete response, epirubicin, cyclophosphamide, paclitaxel, carboplatin, capecitabine, Survival outcomes, Homologous repair deficiency, pembrolizumab
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
920 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Arm A (Platinum-based dose dense EC):
Arm Type
Active Comparator
Arm Description
ddEC x 4 + pembrolizumab→ PK x 4 + pembrolizumab, Two-weekly epirubicin/cyclophosphamide (EC) x 4 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2), followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2). Pembrolizumab is given as a 400 mg iv dosis every 6 weeks for the duration of preoperative chemotherapy.*
Arm Title
Arm B (Platinum-based with capecitabine):
Arm Type
Experimental
Arm Description
CEX x 4→ PK x 4, Three-weekly cyclophosphamide/epirubicin/capecitabine (CEX) (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 and capecitabine 900 mg/m2) x 4, followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).Pembrolizumab is given as a 400 mg iv dosis every 6 weeks for the duration of preoperative chemotherapy.*
*The addition of pembrolizumab is strongly recommended to all participating patients. However, patients with a documented contraindication, or unwilling to receive immunotherapy may be included in the study without the administration of pembrolizumab.
Intervention Type
Drug
Intervention Name(s)
epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab
Other Intervention Name(s)
anthracycline, taxane, platinum
Intervention Description
Cytotoxic agents.
Intervention Type
Drug
Intervention Name(s)
epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab
Other Intervention Name(s)
anthracycline, taxane, antimetabolite, platinum
Intervention Description
Cytotoxic agents.
Primary Outcome Measure Information:
Title
Pathological complete response rate.
Description
Rate of pathological complete response, allowing residual dcis, at surgery after preoperative chemotherapy.
Time Frame
Immediately after surgery
Title
Primary translational outcome.
Description
Pathological complete response rate, allowing residual dcis, stratified for homologous repair deficiency.
Time Frame
Immediately after surgery
Secondary Outcome Measure Information:
Title
Invasive Disease Free Survival (IDFS)
Description
Invasive disease-free survival
Time Frame
Throughout the study, an average of 3 years
Title
Overall Survival (OS)
Description
Overall survival
Time Frame
Throughout the study, an average of 5 years
Title
Breast Cancer Specific Survival (BCSS)
Description
Breast cancer specific survival
Time Frame
Throughout the study, an average of 3 years
Title
Distant Recurrence Free Survival (DRFS)
Description
Distant recurrence free survival.
Time Frame
Throughout the study, an average of 3 years
Title
Dose intensity
Description
Actual dosis/dosis per protocol
Time Frame
Immediately after surgery
Title
Toxicity according to CTCAE version 5.0
Description
Rate of included patients with toxicity grade 3 or greater during study treatment
Time Frame
Immediately after surgery
Other Pre-specified Outcome Measures:
Title
Subset characterization (histological subtypes)
Description
Distribution of different histopathological subsets of Triple Negative Breast Cancer (TNBC).
Time Frame
Immediately after surgery
Title
Subset characterization (germline mutations)
Description
Distribution of subsets of Triple Negative Breast Cancer (TNBC) associated with different inherited breast cancer genes (BRCA1, BRCA2, PALB2, TP53, CHEK2, ATM, RAD51 C and RAD51D).
Time Frame
Immediately after surgery
Title
Subset characterization (somatic mutations)
Description
Distribution of subsets of Triple Negative Breast Cancer (TNBC) associated with somatic mutations, (Eg BRCA1, BRCA2, PALB2, TP53, and other).
Time Frame
Immediately after surgery
Title
Subset characterization (epigenetic alterations)
Description
Distribution of different subsets of Triple Negative Breast Cancer (TNBC) defined based on epigenetic alterations associated with silencing of BRCA1, RAD51 and related HRD-associated genes.
Time Frame
Immediately after surgery
Title
pCR and long term outcome in histologic subsets of TNBC
Description
pCR rate in different histopathological subsets of Triple Negative Breast Cancer (TNBC).
Time Frame
Immediately after surgery
Title
pCR and long term outcome in subsets of TNBC defined based on occurrence of germline genetic alterations
Description
pCR rate in subsets of Triple Negative Breast Cancer (TNBC) associated with different inherited breast cancer genes (BRCA1, BRCA2, PALB2, TP53, CHEK2, ATM, RAD51 C and RAD51D).
Time Frame
Immediately after surgery
Title
pCR and long term outcome in subsets of TNBC defined based on occurrence of somatic genetic alterations
Description
pCR rate in subsets of Triple Negative Breast Cancer (TNBC) associated with somatic mutations, (Eg BRCA1, BRCA2, PALB2, TP53, and other).
Time Frame
Immediately after surgery
Title
pCR and long term outcome in subsets of TNBC defined on epigenetic alterations
Description
pCR rate in different subsets of Triple Negative Breast Cancer (TNBC) based on epigenetic alterations associated with silencing of BRCA1, RAD51 and related HRD-associated genes.
Time Frame
Immediately after surgery
Title
pCR and long term outcome in immun marker defined subsets of TNBC
Description
pCR rate in subsets of Triple Negative Breast Cancer (TNBC) associated with the expression of PDL1.
Time Frame
Immediately after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed written informed consent approved by the Ethical Review Board (IRB).
Age ≥ 18 to < 76 years.
Histologically confirmed unilateral adenocarcinoma of the breast where neoadjuvant chemotherapy followed by definitive surgery is planned.
Node positive disease (N1-3) or if clinically N0 Tumor size >20 mm. When deciding T-stage the following hierarchy applies,
MRI
Ultrasound
Mammography
Clinical examination
ER negative tumor defined by at least one the following:
ER < 1% cells positive by immunohistochemistry (IHC) or ER ≤ 10% cells positive by IHC and basal-like subtype using gene expression analysis
ER < 10% cells positive by IHC and PgR < 10% cells positive by IHC
HER2-normal tumor defined according to applicable national guidelines
Consent for germline mutation screening for BRCA1, BRCA2 and other inherited breast cancer associated genes.
WHO performance status 0 or 1.
Negative pregnancy test in women of childbearing potential (premenopausal or <12 months of amenorrhea post-menopause and who have not undergone surgical sterilization).
Willingness of female patients of childbearing potential, male patients, and their sexual partners to use an effective means of contraception during the treatment period and at least 6 months thereafter.
Willingness by the patient to undergo treatment and study related procedures according to the protocol.
Exclusion Criteria:
Clinical or radiological signs of metastatic disease.
History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or non-melanoma skin cancer.
Previous chemotherapy for cancer or other malignant disease.
Charlson comorbidity index, excluding score for malignancy: (CCI) > 2, Comment: In patients 70-75 a CCI = 3 is allowed, see appendix B.
Inadequate organ function, suggested by the following laboratory results:
a Absolute neutrophil count < 1,5 x 109/L
b Platelet count < 100 x 109/L
c Hemoglobin < 90 g/L
d Total bilirubin greater than the upper limit of normal (ULN) unless the patient has documented Gilbert´s syndrome
e ASAT (SGOT) and/or ALAT (SGPT) > 2,5 x ULN
f ASAT (SGOT) and/or ALAT (SGPT) > 1,5 x ULN with concurrent serum alkaline phosphatase (ALP) > 2,5 x ULN
g Serum creatinine clearance < 50 ml/min
Concurrent peripheral neuropathy of grade 3 or greater (NCI-CTCAE, Version 5.0).
Patient who is actively breast feeding.
Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
Patients with known deficiency of the DPD-enzyme who completely lack DPD.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Niklas Loman, MD, PhD
Phone
+46 46 17 75 20
Email
niklas.loman@med.lu.se
First Name & Middle Initial & Last Name or Official Title & Degree
Lina Zander, RN
Phone
+46 46 17 78 29
Email
nordictrip.onkologi@skane.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Niklas Loman, MD, PhD
Organizational Affiliation
Lund University Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Odense University Hospital
City
Odense
State/Province
Region Syd
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeanette du Pont Jensen, MD
Email
jeanette.dupont.jensen@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Jeanette du Pont Jensen, MD
Facility Name
Vejle Hospital
City
Vejle
State/Province
Region Syd
ZIP/Postal Code
7100
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lone Volmer, MD
Email
lone.volmer@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Lone Volmer, MD
Facility Name
Aalborg Universitetshospita
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sopie Yammeni, MD
Email
s.yammeni@rn.dk
First Name & Middle Initial & Last Name & Degree
Sopie Yammeni, MD
Facility Name
Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulla Brix Tange, MD
Email
Ulla.Brix.Tange@regionh.dk
First Name & Middle Initial & Last Name & Degree
Ulla Brix Tange, MD
Facility Name
Sydvestjysk Sygehus
City
Esbjerg
ZIP/Postal Code
6700
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lone Volmer, MD
Email
Lone.Volmer@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Lone Volmer, MD
Facility Name
Nordsjællands Hospital
City
Hillerød
ZIP/Postal Code
3400
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karin Peschardt, MD
Email
Karin.Peschardt@regionh.dk
First Name & Middle Initial & Last Name & Degree
Karin Peschardt, MD
Facility Name
Regionsjælland Næstved Sygehus
City
Næstved
ZIP/Postal Code
4700
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vesna Glavicic, MD
Email
vga@regionsjaelland.dk
First Name & Middle Initial & Last Name & Degree
Vesna Glavicic, MD
Facility Name
Sønderborg sygehus
City
Sønderborg
ZIP/Postal Code
6300
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erik Hugger Jakobsen, MD
Email
Erik.Hugger.Jakobsen@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Erik Hugger Jakobsen, MD
Facility Name
Vejle syghus
City
Vejle
ZIP/Postal Code
7100
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lone Volmer, MD
Email
Lone.Volmer@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Lone Volmer, MD
Facility Name
Centralsjukhuset i Kristianstad
City
Kristianstad
State/Province
Skåne
ZIP/Postal Code
291 85
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lars Norberg, MD, PhD
Phone
044-309 10 00
Email
Lars.Norberg@skane.se
First Name & Middle Initial & Last Name & Degree
MD, PhD
First Name & Middle Initial & Last Name & Degree
Lars Norberg
Facility Name
Södra Älvsborgs Hospital
City
Borås
ZIP/Postal Code
501 82
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zakaria Einbeigi, MD, PhD
Phone
+46 33 616 10 00
Email
zakaria.einbeigi@oncology.gu.se
First Name & Middle Initial & Last Name & Degree
Zakaria Einbeigi, MD, PhD
Facility Name
Gävle hospital, Department of Oncology
City
Gävle
ZIP/Postal Code
803 24
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Per Edlund, MD, PhD
Phone
+46 26 15 40 00
Email
per.edlund@regiongavleborg.se
First Name & Middle Initial & Last Name & Degree
Per Edlund, MD, PhD
Facility Name
Sahlgrenska University Hospital, Department of Oncology
City
Göteborg
ZIP/Postal Code
413 46
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barbro Linderholm, MD, PhD
Phone
+46 31 342 10 00
Email
barbro.linderholm@ki.se
First Name & Middle Initial & Last Name & Degree
Barbro Linderholm, MD, PhD
Facility Name
Halmstad Hospital, Department of Surgery
City
Halmstad
ZIP/Postal Code
302 33
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alaa Haidar, MD, PhD
Phone
+46 35 13 10 00
Email
alaa.haidar@regionhalland.se
First Name & Middle Initial & Last Name & Degree
Alaa Haidar, MD, PhD
Facility Name
Ryhov Hospital
City
Jönköping
ZIP/Postal Code
551 85
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ida Spång Rosén, MD
Phone
+46 10 241 00 00
Email
ida.spang.rosen@rjl.se
First Name & Middle Initial & Last Name & Degree
Ida Spång Rosén, MD
Facility Name
Karlstad Hospital
City
Karlstad
ZIP/Postal Code
652 30
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kilian Bachmeier, MD
Phone
+46 72 70 39 754
Email
kilian.bachmeier@regionvarmland.se
First Name & Middle Initial & Last Name & Degree
Kilian Bachmeier, MD
Facility Name
Skåne University Hospital, Department of Oncology
City
Malmö
ZIP/Postal Code
20501
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Niklas Loman, MD, PhD
Phone
+46 46 17 75 20
Email
niklas.loman@med.lu.se
First Name & Middle Initial & Last Name & Degree
Rosita Nordkvist, RN
Phone
+46 40 33 28 42
Email
rosita.nordkvist@skane.se
First Name & Middle Initial & Last Name & Degree
Niklas Loman, MD, PhD
Facility Name
Capio S:t Göran Hospital, Department of Oncology
City
Stockholm
ZIP/Postal Code
112 19
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jenny Bergqvist, MD, PhD
Phone
+46 8 587 010 00
Email
jenny.bergkvist@capiostgoran.se
First Name & Middle Initial & Last Name & Degree
Jenny Bergkvist, MD, PhD
Facility Name
Södersjukhuset, Department of Oncology
City
Stockholm
ZIP/Postal Code
118 61
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Camilla Wendt, MD, PhD
Phone
+46 8 616 10 00
Email
cailla.wendt@sll.se
First Name & Middle Initial & Last Name & Degree
Camilla Wendt, MD, PhD
Facility Name
Sundsvall hospital
City
Sundsvall
ZIP/Postal Code
851 86
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna-Karin Wennstig, MD, PhD
Phone
+46 60 18 25 40
Email
annakarin.wennstig@lvn.se
First Name & Middle Initial & Last Name & Degree
Anna-Karin Wennstig, MD, PhD
Facility Name
Norrland University Hospital, Department of Oncology
City
Umeå
ZIP/Postal Code
907 37
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Andersson, MD, PhD
Phone
+46 90 785 00 00
Email
anne.andersson@umu.se
First Name & Middle Initial & Last Name & Degree
Anne Andersson, MD, PhD
Facility Name
Academical Hospital, Department of Oncology
City
Uppsala
ZIP/Postal Code
753 09
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henrik Lindman, MD, PhD
Phone
+46 18 611 00 00
Email
henrik.lindman@igp.uu.se
First Name & Middle Initial & Last Name & Degree
Henrik Lindman, MD, PhD
Facility Name
Västmanlands Hopsital Västerås
City
Västerås
ZIP/Postal Code
721 89
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cecilia Nilsson, MD, PhD
Phone
+46 21 30 00
Email
Cecilia.nilsson@regionvastmanland.se
First Name & Middle Initial & Last Name & Degree
Cecilia Nilsson, MD, PhD
Facility Name
Växjö Hospital, Department of Oncology
City
Växjö
ZIP/Postal Code
352 34
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulrik Narbe, MD, PhD
Phone
+46 470 58 80 00
Email
ulrik.narbe@med.lu.se
First Name & Middle Initial & Last Name & Degree
Ulrik Narbe, MD, PhD
Facility Name
Örebro University Hospital, Department of Oncology
City
Örebro
ZIP/Postal Code
701 85
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonis Valachis, MD, PhD
Phone
+46 19 602 10 00
Email
antonis.valachis@igp.uu.se
First Name & Middle Initial & Last Name & Degree
Antonis Valachis, MD, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
We'll reach out to this number within 24 hrs